Integrated resources to move regenerative therapies toward the clinic

MN-BRIDGE provides a comprehensive preclinical translation platform designed to de-risk regenerative medicine (RM) therapies and accelerate their progression toward first-in-human studies. Central to this platform is our deep expertise in primate immunology and assay development, enabling high-fidelity evaluation of safety, efficacy, and immune response in models that closely reflect human biology.

By integrating new approach methodologies with translational NHP models, a high-value biorepository, purpose-built immunological assays, and regulatory-aligned workflows, we help investigators generate translation-ready data that meaningfully inform clinical decision-making while reducing cost, risk, and time to clinic.

NHP Models & Biobank
A sustainable biological foundation for translational research
Our preclinical translation support is anchored by a well-characterized NHP resource, including a shared biobank and access to our world class primate resource. This enables both in vitro and in vivo studies while reducing redundancy and accelerating study startup.

What we provide:

• A no-cost NHP biobank with tissues, cells, and biofluids
• Access to serum, plasma, whole blood, cryopreserved PBMCs, urine, and tissues
• Digital pathology resources and associated metadata
• Robust control datasets and in silco modeling to reduce animal use

Designed to support reproducibility, efficiency, and long-term sustainability.

Immunology & Assay Development
Understanding immune response is critical for RM translation

Immune responses—such as cytokine release, T cell activation, inflammation, and immune-mediated loss of efficacy—are among the most significant barriers to successful RM translation. MN-BRIDGE addresses this challenge by developing and validating NHP-specific immunological assays that capture the complexity of a fully educated immune system.

What we provide:

• Qualification and validation of NHP-specific assays for RM applications
• Cytokine profiling, immune phenotyping, and inflammatory marker analysis
• Humoral and cellular immunogenicity assessments for cells, vectors, and biologics
• Baseline characterization of the naïve NHP immune landscape
• GLP-aligned workflows and standardized reporting suitable for IND/IDE submissions

These tools enable precise, mechanism-informed evaluation of immune risk and therapeutic performance.


Exploratory studies: Generating the data needed to move forward with confidence

MN-BRIDGE supports exploratory preclinical studies that address the key translational questions required for clinical advancement.

Support includes:

• Exploratory safety and efficacy studies
• Immunogenicity risk assessment and mitigation strategies
• Development of precision immunomodulatory regimens
• Dose optimization and feasibility evaluations
• Integration of pre-existing datasets to accelerate timelines

Helping teams identify the most promising therapies and avoid costly missteps.


Why This Matters
Regenerative therapies often fail not because they lack promise, but because immune risks and translational uncertainties are discovered too late. MN-BRIDGE enables investigators to address these challenges early, using validated assays, expert immunology insight, and predictive NHP models—before committing to expensive clinical trials.